DMAAU
Drugs Made In America Acquisition Corp.
Financial Services — Shell Companies
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
None
$10.79
(0.00%)
Price History
52-Week Range
Sign in to add DMAAU to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 100.0 |
| Beta | - |
| SMA 20 | $10.85 |
| SMA 40 | $10.89 |
| 52-Week High | $12.50 |
| 52-Week Low | $10.30 |
| 50-Day Avg | $10.87 |
| 200-Day Avg | $10.61 |
| Avg Volume | 644 |
| Volume | 4 |
Performance Analysis
NEUTRALDMAAU presents a mixed picture with both positive and negative indicators.
~
Trading at 22% of its 52-week range.
-
RSI at 100.0 indicates overbought conditions — a pullback may be due.
~
Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 01, 2026 04:14 UTC
Back to Screener Export Report